FDA Publishes Its Playbook for Fast-Track CMC Readiness

FDA has told sponsors, on paper, how it intends to keep manufacturing questions from derailing drugs and biologics developed on accelerated timelines. On 23 July 2026, the agency published its Strategy Document on Facilitating Chemistry, Manufacturing, and Controls Readiness for Products With Accelerated Clinical Development — a Federal Register notice that closes out a three-year pilot with a written plan for what comes next, through the end of fiscal year 2027.

A user-fee commitment, made good

PDUFA VII, the current five-year user-fee agreement covering fiscal years 2023 through 2027, is where this obligation was written down. FDA committed to advance its capability to facilitate CMC development for sponsors of CDER- and CBER-regulated drugs and biologics intended to diagnose, treat, or prevent a serious disease or condition where there is an unmet medical need — the same category of product that, by definition, is racing a clinical timeline its manufacturing process was not necessarily built to match. The Strategy Document is FDA discharging that commitment in writing, rather than leaving it as a negotiating-table promise.

Built on a three-year pilot

The document does not arrive from nothing. Since April 2023, FDA has run the Chemistry, Manufacturing, and Controls Development and Readiness Pilot — CDRP — to give sponsors filing an IND on an accelerated clinical development timeframe more structured, earlier engagement with the agency's CMC reviewers, rather than waiting for a marketing-application review to surface a manufacturing gap. On 10 September 2025, FDA co-sponsored a public workshop with the Duke-Margolis Center for Health Policy specifically on lessons learned from running the pilot. The Strategy Document is where those lessons turn into a stated plan: what FDA has already done, and what it intends to do across FY 2026 and FY 2027, while the pilot keeps running for as long as PDUFA VII stays in effect.

Why CMC readiness is the operational bottleneck

For a small-molecule generic, manufacturing and clinical development mostly run on separate clocks. For an accelerated cell or gene therapy, they do not: the product often changes between early trials and a pivotal filing, which means the CMC package has to keep proving comparability while the clinical package is racing toward a filing date. That is precisely the failure mode behind FDA's Complete Response Letter to Capricor's deramiocel BLA last July, which cited unresolved CMC items alongside its efficacy findings — a sponsor with a defensible clinical story still getting the harder kind of rejection. A strategy document does not rewrite that dynamic. It is FDA saying, in the clearest form a Federal Register notice allows, that it has been watching where accelerated programs actually stall, and it is telling sponsors what changes as a result.

• April 2023 — FDA launches the CMC Development and Readiness Pilot (CDRP) for eligible IND sponsors on accelerated timelines.
• 10 September 2025 — FDA and the Duke-Margolis Center for Health Policy co-host a public workshop on lessons learned from the pilot.
• 23 July 2026 — FDA publishes its Strategy Document, Docket FDA-2026-N-7232, setting out actions taken and its FY 2026–2027 plan.
• End of FY 2027 — PDUFA VII, and the CDRP pilot it authorizes, is currently set to expire.